Robert Ragusa serves as the Chief Executive Officer at GRAIL, Inc., a company focused on early cancer detection through innovative blood tests. With a robust background in the life sciences and diagnostics industry, Ragusa has been instrumental in steering GRAIL towards its mission of transforming cancer care. Before joining GRAIL, he held significant leadership roles that prepared him for his current position. Notably, he was the Chief Operating Officer at Verily Life Sciences, where he played a key role in scaling operations and driving the development of multiple healthcare solutions. At GRAIL, Ragusa's leadership has been pivotal in advancing the company’s flagship product, Galleri, a multi-cancer early detection test that has the potential to revolutionize cancer screening. Under his guidance, GRAIL has successfully navigated the complex landscape of clinical validation and regulatory approval, bringing the company closer to widespread adoption of its technology. His strategic vision extends beyond product development to include building robust partnerships and enhancing GRAIL’s global presence, ensuring that the benefits of early cancer detection reach a broader audience. Ragusa's achievements are not only confined to his role at GRAIL but also reflect his broader impact on the healthcare industry. His experience in operational excellence and his ability to foster innovation have earned him recognition as a thought leader in the field. As CEO, he continues to champion GRAIL's mission, emphasizing the importance of early detection in improving patient outcomes and ultimately saving lives. His dedication to advancing healthcare through technology positions GRAIL as a leader in the fight against cancer.